Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to -$66.7 million.

  • Gyre Therapeutics' Retained Earnings rose 912.4% to -$66.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year increase of 912.4%. This contributed to the annual value of -$73.5 million for FY2024, which is 1412.82% up from last year.
  • As of Q3 2025, Gyre Therapeutics' Retained Earnings stood at -$66.7 million, which was up 912.4% from -$70.3 million recorded in Q2 2025.
  • Gyre Therapeutics' Retained Earnings' 5-year high stood at $7.4 million during Q4 2022, with a 5-year trough of -$417.2 million in Q1 2022.
  • Its 5-year average for Retained Earnings is -$234.6 million, with a median of -$337.2 million in 2021.
  • Per our database at Business Quant, Gyre Therapeutics' Retained Earnings soared by 10183.64% in 2022 and then plummeted by 125670.05% in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Retained Earnings stood at -$402.7 million in 2021, then surged by 101.84% to $7.4 million in 2022, then crashed by 1256.7% to -$85.5 million in 2023, then grew by 14.13% to -$73.5 million in 2024, then increased by 9.19% to -$66.7 million in 2025.
  • Its last three reported values are -$66.7 million in Q3 2025, -$70.3 million for Q2 2025, and -$70.8 million during Q1 2025.